Researchers found that Avlayah, a new enzyme replacement therapy, has received accelerated approval from the U.S. Food and Drug Administration (FDA) for treating neurological symptoms of Hunter syndrome in children. This condition affects the body’s ability to break down certain sugars, leading to a buildup that can cause serious health issues. Avlayah is designed for pediatric patients who weigh at least 5 kg and can be started before significant neurological impairment occurs.

This therapy could be a game-changer for families dealing with Hunter syndrome, as it has shown a remarkable 91% reduction in a harmful substance in the cerebrospinal fluid after 24 weeks of treatment. In fact, 93% of the children treated saw their levels return to normal. For parents looking for effective options to help their children maintain better neurological health, this therapy offers hope, especially if initiated early.

However, it’s important to note that the evidence is still in the early stages. The approval was based on Phase 1/2 trial data, and ongoing research in the Phase 2/3 COMPASS study will provide further confirmation of its effectiveness. While the initial results are promising, continued approval will depend on the outcomes of these larger studies. Parents should discuss with their healthcare providers to understand the best course of action for their children.

Source: longevity.technology